Wallington Asset Management LLC Has $12.79 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Wallington Asset Management LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 0.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 88,417 shares of the company’s stock after acquiring an additional 93 shares during the period. Johnson & Johnson makes up about 1.8% of Wallington Asset Management LLC’s holdings, making the stock its 24th largest position. Wallington Asset Management LLC’s holdings in Johnson & Johnson were worth $12,787,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Vinva Investment Management Ltd boosted its position in shares of Johnson & Johnson by 6.8% during the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock valued at $17,988,000 after buying an additional 7,110 shares during the last quarter. Financial Counselors Inc. grew its stake in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock worth $29,996,000 after acquiring an additional 9,309 shares in the last quarter. Meridian Investment Counsel Inc. raised its holdings in shares of Johnson & Johnson by 19.6% in the third quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock valued at $3,667,000 after purchasing an additional 3,710 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Johnson & Johnson by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock valued at $2,858,543,000 after purchasing an additional 102,502 shares in the last quarter. Finally, Lord Abbett & CO. LLC bought a new stake in Johnson & Johnson in the 3rd quarter worth about $69,859,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently commented on the company. Wells Fargo & Company lifted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Wolfe Research started coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target for the company. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Citigroup decreased their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, Bank of America dropped their price objective on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a research note on Friday. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $174.29.

Johnson & Johnson Price Performance

JNJ stock opened at $147.03 on Monday. The firm has a 50 day moving average of $148.51 and a 200-day moving average of $156.03. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $353.99 billion, a P/E ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.